Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists

Neuropharmacology. 1997 Sep;36(9):1327-38. doi: 10.1016/s0028-3908(97)00139-1.

Abstract

The effects of nonselective (theophylline), A1-(DPCPX) or A2A-selective (SCH 58261) adenosine receptor antagonists administered before or after neonatal hypoxia-ischemia (HI) were studied on the extent of brain injury in 7-day-old rats evaluated after 14 days. A possible effect of theophylline (20 mg/kg) on expression of immediate early genes was studied with in situ hybridization. Theophylline (20, 30 or 60 mg/kg) given prior to HI reduced brain damage by 48% (P < 0.001), 36% (P < 0.01) and 34% (P < 0.05), respectively, compared to control rats. This effect was not explained by changes in temperature, cerebral blood flow, blood gas/acid base status or blood glucose during the insult. Theophylline enhanced the upregulation of c-fos and NFGI-A during reperfusion but did not prevent the decrease in adenosine A1 receptor mRNA. Posttreatment with SCH 58261 (0.2 or 2 mg/kg) reduced brain damage by 19% (P < 0.05) and 14% (NS), respectively, compared to control rats which was unrelated to the core temperature. DPCPX (2 or 10 mg/kg) had no effect on the development of brain injury. In conclusion, nonselective and A2A adenosine receptor antagonists reduced brain injury in a model of HI in immature animals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Blood Gas Analysis
  • Blood Glucose / analysis
  • Body Temperature / drug effects
  • Body Weight / drug effects
  • Brain / pathology
  • Brain Ischemia / pathology
  • Brain Ischemia / physiopathology*
  • Cerebrovascular Circulation / drug effects
  • Female
  • Hypoxia, Brain / pathology
  • Hypoxia, Brain / physiopathology*
  • Male
  • Purinergic P1 Receptor Antagonists*
  • Pyrimidines / pharmacology
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A2A
  • Theophylline / pharmacology
  • Triazoles / pharmacology
  • Xanthines / pharmacology

Substances

  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Blood Glucose
  • Purinergic P1 Receptor Antagonists
  • Pyrimidines
  • RNA, Messenger
  • Receptor, Adenosine A2A
  • Triazoles
  • Xanthines
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Theophylline